Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer - PubMed (original) (raw)

Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer

Iván Roa et al. Gastrointest Cancer Res. 2014 Mar.

Abstract

Background: The HER2/neu gene is a proto-oncogene that can predict the response to treatment with trastuzumab, pertuzumab, and lapatinib. This study was conducted to determine the frequency of HER2/neu overexpression and to identify a subgroup of patients with gallbladder cancer who would benefit from targeted therapy.

Methods: Patients with gallbladder cancer (n = 187; 165 women and 22 men) with a recorded follow-up of at least 5 years were included, along with control subjects (n = 75). An automated immunohistochemical technique was used with an anti-ErbB2 antibody. Scoring was conducted according to the CAP/ASCO (College of American Pathologists/American Society of Clinical Oncology) criteria for breast cancer.

Results: Overexpression of HER2/neu was observed in 12.8% of the cases. Of those, 0% were mucosal, 14.3% muscular, 12.8% subserosal, and 10.6% serosal. In 20% of the cases, equivocal staining was observed. Overexpression was more frequent in the advanced cancers and in the better differentiated tumors (13.8% and 17.4%, respectively), but the difference was nonsignificant. The patients with overexpression of HER2/neu had a worse overall survival, when compared with those who had no expression at 5 years (34% vs. 41%).

Conclusion: This is the single largest study of HER2/neu expression in gallbladder cancer to use commonly accepted scoring criteria. The results indicate that HER2/neu overexpression occurred in 14% of the advanced gallbladder cancer cases. This subgroup may benefit from inhibitors of the HER2/neu pathway.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

HER2/neu immunohistochemical staining: (A) focal, weak (1+) positivity in the superficial area of the mucosa in pyloric metaplasia; (B) positive basolateral membrane staining (2+) in intestinal metaplasia; and (C, D) gallbladder adenocarcinoma with strong membrane-positive staining (+3) in more than 30% of the tumor cells.

Figure 2.

Figure 2.

Top: actuarial survival of the total group according to the level of tumor infiltration of the gallbladder wall; bottom: survival curves in patients with (positive) and without (negative) HER2 overexpression. Patients with overexpression had a worse survival rate; however, the difference was not significant.

References

    1. Eslick GD: Epidemiology of gallbladder cancer. Gastroenterol Clin North Am 39:307–330, 2010 - PubMed
    1. Andia ME, Hsing AW, Andreotti G, et al. : Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study. Int J Cancer 123:1411–1416, 2008 - PMC - PubMed
    1. Andia KM, Gederlini GA, Ferreccio RC: [Gallbladder cancer: trend and risk distribution in Chile]. Rev Med Chil 134:565–574, 2006 - PubMed
    1. Begnami MD, Fukuda E, Fregnani JH, et al. : Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29:3030–3036, 2011 - PubMed
    1. Tafe LJ, Tsongalis GJ: The human epidermal growth factor receptor 2 (HER2). Clin Chem Lab Med 50:23–30, 2012 - PubMed

LinkOut - more resources